The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality.5,7–9,11,30”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, modern treatment guidelines for type 2 diabetes 154 and essential hypertension 155 (also nutrition related chronic diseases), do recommend a stepped care approach to pharmacotherapy.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [154]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“However, a 5% weight reduction is insufficient to improve many aspects of health, and greater weight losses confer greater benefits, 23,82,83 with some data suggesting that there may be a threshold effect for reduction in some important comorbidities such as CVD and diabetes remission.[84][85][86]”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation
Flagged first, then by citations
2 of the 114 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Sorted by citations
Items 401–500 of 852
Seufert, J., Freemantle, N., Guja, C., Haluzı́k, M., Tournay, M., Vera, C., Bonnemaire, M., & Kis, J. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15609 · Cited by 5
Chronic kidney disease progression in diabetic patients: Real world data in general practice
Rottura, M., Drago, S. F. A., Gianguzzo, V. M., Molonia, A., Pallio, G., Scoglio, R., Marino, S., Alibrandi, A., Imbalzano, E., Squadrito, F., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30787 · Cited by 7
Shared decision-making approach to type 2 diabetes management
MacDonald, B. J., McCormack, J. P., & Turgeon, R. D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7005310 · Cited by 5
Denny, O., Baron, J. I., & Albanese, N. P. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241256775 · Cited by 5
Insulin for people with type 2 diabetes mellitus
Vanderpant, N., Ward, E., Farrell, E., & Theodoraki, A. (2024) · BMJ · doi:10.1136/bmj-2023-078015 · Cited by 6
Insights into insulin analog cross-reactivity: a comparative study of Siemens Atellica and LC-MS/MS
Li, J., Hatten-Beck, M., Lee, J. K. Y., & Hoofnagle, A. N. (2024) · Endocrine · doi:10.1007/s12020-024-03970-6 · Cited by 5
Nguyễn, H. L. T., Ha, T. T., Nguyen, N. P. N., Phan, N., Nguyen, D. T. H., Dat, T. V., Truong, M.-N., Nguyen-Hoang, T.-M., Luu, T. N., Nguyen, N. P., et al. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e126255 · Cited by 5
The Impact of Genetic Polymorphisms on the Anti-Hyperglycemic Effect of Dapagliflozin
Wang, Z., Li, X., Xu, Q., Yao, Y., Li, X., Yan, H., & Lv, Q. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s464671 · Cited by 7
Bosi, A., Xu, Y., Faucon, A., Huang, T., Evans, M., Shin, J., Fu, E. L., & Carrero, J. J. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae227 · Cited by 5
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Tomlinson, B., & Li, Y. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2276180 · Cited by 5
Kim, J. H., Lyu, Y. S., Kim, B., Kim, M. K., Kim, S. Y., Baek, K., Song, K., Han, K., & Kwon, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15565 · Cited by 5
Morello, C. M., Awdishu, L., Lam, S., Heman, A., & Bounthavong, M. (2024) · Kidney360 · doi:10.34067/kid.0000000597 · Cited by 6
Tartau, C. G., Boboc, I. K. Ş., Mititelu-Tarțău, L., Bogdán, M., Bucă, B. R., Pavel, L. L., & Amălinei, C. (2025) · Pharmaceuticals · doi:10.3390/ph18050670 · Cited by 4
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 7
Tawanwongsri, W., Mordmuang, A., Phenwan, T., & Siri-Archawawat, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1680647 · Cited by 4
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 5
Kim, H. J., Noh, J. H., Moon, M. K., Choi, S. H., Ko, S., Rhee, E., Hur, K. Y., & Jeong, I. (2024) · Journal of Diabetes Research · doi:10.1155/2024/8915591 · Cited by 4
Longo, M., Caruso, P., Scappaticcio, L., Maiorino, M. I., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15451 · Cited by 4
Hofner, M., Hurnaus, P., DiStefano, D., Philip, S., Kim, S., Shaw, J. L. V., & Waring, A. C. (2024) · JMIR Diabetes · doi:10.2196/53835 · Cited by 5
Carrillo-Larco, R. M., Guzman‐Vilca, W. C., Varghese, J. S., Pasquel, F. J., Caixeta, R. D. B., Antini, C., & Bernabé‐Ortiz, A. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.03.001 · Cited by 11
Newson, R. S., Spaepen, E., Liao, B., Bower, J. K., Bhattacharya, I., Artime, E., & Polonsky, W. H. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02390-9 · Cited by 4
Nicolaisen, S. K., le Cessie, S., Thomsen, R. W., Witte, D. R., Dekkers, O. M., Sørensen, H. T., & Pedersen, L. H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111722 · Cited by 4
Polypeptides-Based Nanocarriers in Tumor Therapy
You, J., Guo, Y., & Dong, Z. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091192 · Cited by 4
Dagnew, S. B., Wondm, S. A., Tarekegn, G. Y., Kassaw, A. T., & Moges, T. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1450928 · Cited by 4
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70313 · Cited by 4
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners
Kesavadev, J., Basanth, A., Shankar, A., Saboo, B., Mohan, A. R., Joshi, S., Ghosh, S., Krishnan, G., Jothydev, K., & Ashik, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03250-3 · Cited by 4
Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context
Seshadri, K., Mohan, V., WANGNOO, S. K., Sosale, A., Saboo, B., Sahay, R. K., Polisetti, S., & Kolukula, V. K. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0938 · Cited by 4
Yang, I. G., Kim, J. S., & Kang, M. J. (2025) · Nanomaterials · doi:10.3390/nano15181399 · Cited by 4
Artz, A. S., Nguyen, T., Samoa, R. A., Kim, H., Tse, W., Jin, R., & Goutnik, S. (2025) · Advances in Hematology · doi:10.1155/ah/7244013 · Cited by 4
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C.-C. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105901 · Cited by 5
Zhong, Z., Zhao, S., He, W., Li, R., & Xia, S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.106065 · Cited by 4
Tiley, J. B., Hartauer, M., Whigham, T. L., Mendes, M. D. S., Brouwer, K. L. R., & Hébert, M. F. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70136 · Cited by 4
Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes
Cai, C. X., Toy, B. C., Martin, B., Ruochong, F. A. N., Westlund, E., Tran, D., Nishimura, A., Lee, H., Leng, T., Nagy, P. G., et al. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.05.034 · Cited by 4
OKADA, M., Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6284 · Cited by 4
Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy
Bando, H., Yamashita, H., Kato, Y., OGURA, K., & Kato, Y. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6293 · Cited by 4
Ouchi, D., Giner‐Soriano, M., Vilaplana-Carnerero, C., Monfà, R., Torres, F., & Morros, R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110777 · Cited by 4
Wander, P. L., Lowy, E., Korpak, A. M., Beste, L. A., Kahn, S. E., & Boyko, E. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100151 · Cited by 4
O’Brien, M. J., Bailey, S. C., Gregory, D. L., Owen, A. L., Khan, S. S., Ackermann, R. T., Hassan, A., Mohanty, N., & Bowen, M. E. (2023) · Journal of general internal medicine · doi:10.1007/s11606-023-08402-1 · Cited by 9
Alawainati, M., Ayoob, Z. A., & Naser, H. S. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_829_23 · Cited by 5
Strategies to Maintain the Remission of Diabetes Following Metabolic Surgery
Kim, M. K., & Kim, H. S. (2023) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2023.12.2.26 · Cited by 5
Sloan, L. A., CHENG, A. Y. Y., Escalada, J., Haluzı́k, M., & Mauricio, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15425 · Cited by 4
Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective
Kalra, S., Zargar, A. H., Sridhar, G. R., Das, A. K., Ahmed, J., Mohan, J. C., Vijayakumar, G., Kumar, A., Sahay, R. K., Ayer, V., et al. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514231203911 · Cited by 4
Xie, Z., Hu, J., Li, M., Hu, X. X., & Chen, J. (2024) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s455897 · Cited by 4
Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
Bafna, A. A., Mehta, A., Garg, R., Balagopalan, J. P., Rajput, R., Zalte, N., Naik, P., Sugumaran, A., & Mohanasundaram, S. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_115_23 · Cited by 4
NEYER, M., Vogel, J. B., ELSNER, P., Kuehrer, H., Saely, C. H., Muendlein, A., Vonbank, A., MADER, A., Festa, A., Drexel, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16084 · Cited by 4
Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
Bae, J. H., Choi, J., Kim, N. H., & Kim, S. G. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.015 · Cited by 5
Temporelli, P. L. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae086 · Cited by 5
Riaz, M., Waris, N., Hossain, N., & Talpur, N. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112206 · Cited by 4
Wearable ultrasound regulation of blood glucose levels in type 2 diabetic db/db mice
Yang, Y., Jin, Z., Zhou, H., Li, Y., Zhang, W., Xiang, Y., Wu, D., Li, F., & Li, F. (2025) · Ultrasonics · doi:10.1016/j.ultras.2025.107739 · Cited by 4
Loss of β‐cell identity in human islets treated with glibenclamide
Fernández, C., Nacher, M., Rivera, K., Marín‐Cañas, S., Sorribas, M., Moreno‐González, G., Estil·les, E., José, P. S., Téllez, N., & Montanya, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16632 · Cited by 3
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease
Krishnaraj, A., Bakbak, E., Teoh, H., Bhatt, D. L., Quan, A., Puar, P., Lambotharan, B., Kirubaharan, A., Firoz, I. N., Meglis, G., et al. (2023) · Med · doi:10.1016/j.medj.2022.12.008 · Cited by 4
Seo, M. H. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.1.5 · Cited by 4
McDaniel, C. C., Lo‐Ciganic, W., Garza, K. B., Kavookjian, J., Fox, B. I., & Chou, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1158454 · Cited by 4
Starr, J. A., & Pinner, N. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231189508 · Cited by 4
Comparison of Insulin Analogs and Human Insulins: A Narrative Review
Eledrisi, M. S., & Danjuma, M. I.-M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1771027 · Cited by 4
Glucocentric and cardiocentric approaches to achieving type 2 diabetes compensation
Pankiv, V. І. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.5.2023.1297 · Cited by 4
Pilla, S. J., Meza, K. A., Beach, M. C., Long, J. A., Gordon, H. S., Bates, J. T., Washington, D. L., Bokhour, B. G., Tuepker, A., Saha, S., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100641 · Cited by 4
Erukulapati, R. S., Manikandan, R. M., Jakkidi, L. R., Sathyanarayana, S. O., Ayyagari, U., Aswathiah, S., Nalla, S., Sampath, S. K., Manohar, S. P., Shah, S. C., et al. (2024) · Clinical Diabetology · doi:10.5603/cd.98136 · Cited by 5
Hu, S., Shi, C., Ma, Y., Wang, S., Gu, S., Qi, C., & Fan, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15645 · Cited by 4
Arenas-León, J. L., Morales-Villegas, E., Cardona-Muñóz, E. G., Alcocer-Gamba, M. A., Ramirez-Contreras, J. P., Contreras-Sandoval, A. Y., & González-Gálvez, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01231-6 · Cited by 4
Kamrul-Hasan, A. B. M., Alam, M. S., Talukder, S. K., Hannan, M. A., Dutta, D., Nagendra, L., & Selim, S. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5553327 · Cited by 3
Steiger, K. G., SWARNA, K. S., Herrin, J. S., & McCoy, R. G. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09784-0 · Cited by 4
Tsai, M., Lee, W., Huang, S., Huang, C.-C., Wang, Y., Yuan, C., Wang, C.-C., Liu, C.-H., Huang, N., Chang, Y., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117512 · Cited by 3
Empagliflozin and fluid balance: results from the SiRENA project
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf262 · Cited by 3
Metformin mitigates aortic valve degeneration in an ex vivo three-dimensional tissue model
Schoettler, F. I., Weber, A., Schmidt, V., Bauer, S. J., Immohr, M. B., Lichtenberg, A., Akhyari, P., & Barth, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-31070-6 · Cited by 3
Du, F., Ospina, N. S., Chen, Y., Brito, J. P., Liu, Q., Schmidt, S., McCoy, R. G., Cicali, B., Shao, H., & Jiao, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02971-7 · Cited by 3
Badran, A., Gbreel, M. I., Tawfik, A. M., & Balata, M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02080-1 · Cited by 3
Dong, Y., Huang, X., Hao, M., Li, H., & Yan, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1762526 · Cited by 3
Kıraç, C. O., Şirikçi, V., & Fındıklı, H. A. (2023) · Medicine · doi:10.1097/md.0000000000034696 · Cited by 3
Giandalia, A., Nicolucci, A., Modugno, M., Lucisano, G., Rossi, M. C., Manicardi, V., Rocca, A., Cianni, G. D., Bartolo, P. D., Candido, R., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02306-5 · Cited by 4
Metabolic-Bariatric Surgery for Type 2 Diabetes: Time(ing) for a Change
Purnell, J. Q. (2024) · Diabetes · doi:10.2337/dbi23-0022 · Cited by 3
Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients
Secin, A. A. R., Díez‐Espino, J., Prieto-Díaz, M. Á., Pallarés‐Carratalá, V., Barquilla-García, A., Micó-Pérez, R. M., García, J. P., Velilla-Zancada, S. M., Martín, V., Segura‐Fragoso, A., et al. (2024) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2024.102220 · Cited by 4
Metformin for Type 2 diabetes mellitus
MacDonald, B. J., Turgeon, R. D., & McCormack, J. P. (2024) · Academic Emergency Medicine · doi:10.1111/acem.14922 · Cited by 3
Çöllüoğlu, T., Çelik, A., Ata, N., Ural, D., Şahin, A., Ülgü, M. M., Kanık, E. A., Birinci, Ş., & Yılmaz, M. B. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132109 · Cited by 4
FARSANI, S. F. F., Iglay, K., Zhang, L., Niyonkuru, C., Nessralla, L., & Girman, C. J. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5800 · Cited by 3
Pen needle use patterns in an insured population with diabetes: U.S. retrospective claims analysis
Lupton, L. L., Sun, X., Javadi, P., Goldman, J. D., Cornell, S. A., Fernandes, J., Kishorekumar, S., Thach, A., & Sieradzan, R. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102124 · Cited by 3
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
Kiyohara, K., Kondo, N., Iwami, T., Yano, Y., Nishiyama, A., Node, K., Inagaki, N., Duru, O. K., & Inoue, K. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033860 · Cited by 3
Barakat, S., Ramdeen, S., & Khaimova, R. (2024) · Hospital Pharmacy · doi:10.1177/00185787241266803 · Cited by 3
Shinohara, Y., Jojima, T., Kamiga, Y., Sakurai, S., Iijima, T., Tomaru, T., AKUTSU, I., Inoue, T., Usui, I., & Aso, Y. (2024) · Medical Principles and Practice · doi:10.1159/000540852 · Cited by 4
Khayyat, S. M., Ali, R. S. A., Alrammaal, H. H., Khayyat, S. M. S., Alqurashi, W. A., Alsaedi, R., Alotaibi, W. A., & AL‐AHMADI, A. A. (2024) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2024.296 · Cited by 3
Dai, J., Chang, J. J., Choi, J. M., Bullock, A. K., Manson, S. M., O’Connell, J., & Jiang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16021 · Cited by 3
Rashid, S. A., Madar, I. H., Misbah, I., Dhanabalan, K., Balasubramanian, R., & Maideen, N. M. P. (2025) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0045-1805026 · Cited by 4
Low-carbohydrate diet in type 1 diabetes: A systematic review
Sousa, S. S. D. S., Nery, E. S., & Giuffrida, F. M. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.009 · Cited by 5
Bazan, D. Z., Esqueda, L., Ibrahim, A., Gonzalez, L., Skubic, J. J., Reilly, J., Cavazos, R. G., & Verduzco, R. (2025) · Cureus · doi:10.7759/cureus.84665 · Cited by 3
Abegaz, T. M., & Ali, A. A. (2023) · Healthcare · doi:10.3390/healthcare11040541 · Cited by 3
Weeda, E. R., Ward, R. C., Gebregziabher, M., Axon, R. N., & Taber, D. J. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-023-01619-0 · Cited by 3
Mohammad, I., Poyer, A., Hamoud, R., & George, J. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i1.5444 · Cited by 4
Bea, S., Choi, A., Kim, J. H., Cho, Y. M., Choi, W. S., Jung, J., & Shin, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15163 · Cited by 4
Molfetta, S. D., Laviola, L., Natalicchio, A., Leonardini, A., Cignarelli, A., Bonizzoni, E., Acmet, E., & Giorgino, F. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110836 · Cited by 4
Kosjerina, V., Carstensen, B., Amadid, H., & Vistisen, D. (2023) · Diabetologia · doi:10.1007/s00125-023-05971-y · Cited by 3
Ito, H., Inoue, H., Izutsu, T., Matsumoto, S., Antoku, S., Yamasaki, T., Mori, T., & Togane, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292014 · Cited by 3
In Silico Validation of Personalized Safe Intervals for Carbohydrate Counting Errors
Amorim, D., Miranda, F., & Abreu, C. (2023) · Nutrients · doi:10.3390/nu15194110 · Cited by 3
Harris, S. B., Mohammedi, K., Bertolini, M., Carlyle, M. H., Walker, V., Zhou, F. L., Anderson, J. E., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15240 · Cited by 4
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
Zhu, J., & Wilding, J. P. H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01181-4 · Cited by 3
Angelino, S., CARUSO, P., Longo, M., Barrasso, M., Castaldo, F., Pontillo, A., Arena, S., Palmieri, A., Bellastella, G., Maiorino, M. I., et al. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04096-4 · Cited by 3
Sun, J., Xie, Z., Ye, M., He, X., Dong, Y., Liu, C., & Zhu, W. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14689 · Cited by 2
Gara, H. K., & Vanamali, D. R. (2024) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_73_2023 · Cited by 3
Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
Valencia, C. M. B., Ramos, A. F. G., Osorio-Toro, L. M., Ordoñez-Guzman, Y. A., Gómez, N. B., López, W., Vizcaino-Guerrero, C., Daza-Arana, J. E., Rincón, A. R., & Restrepo-Erazo, K. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443115 · Cited by 3
Saito, M., Usui, I., Sugawara, N., Jojima, T., Sakurai, S., Kishi, H., Sagara, M., Tomaru, T., Iijima, T., Shimoda, K., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00721-w · Cited by 3
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S140-S157
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810476
- OpenAlex
- W4311264067
- Semantic Scholar
- f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
- Cited by
- 851
- References
- 114
- Citations by year
- 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
- FWCI
- 28.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
